# Alamar Biosciences Inc. (ALMR)

Source: https://www.quantisnow.com/company/ALMR
Generated: 2026-11-14T15:41:45.414Z

- Ticker: ALMR
- Exchange: NASDAQ
- Sector: Industrials
- Industry: Biotechnology: Laboratory Analytical Instruments
- IPO year: 2026
- SEC CIK: 0002104204

## Latest ALMR news and filings

- 2026-11-14 02:02 UTC [SEC Form 4] [Large owner Qiming Corporate Gp Vi, Ltd. sold $2,941,571 worth of shares (100,117 units at $29.38) (SEC Form 4)](https://www.quantisnow.com/insight/large-owner-qiming-corporate-gp-vi-ltd-sold-2941571-worth-6791788)
- 2026-11-05 21:10 UTC [SEC Form 4] [Large owner Qiming Corporate Gp Vi, Ltd. sold $3,327,146 worth of shares (111,313 units at $29.89) (SEC Form 4)](https://www.quantisnow.com/insight/large-owner-qiming-corporate-gp-vi-ltd-sold-3327146-worth-6776450)
- 2026-11-04 21:05 UTC [Conference Announcement] [Alamar Biosciences to Participate in Upcoming Investor Conferences](https://www.quantisnow.com/insight/alamar-biosciences-to-participate-in-upcoming-investor-conferences-6772286)
- 2026-11-04 02:00 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Alamar Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-alamar-biosciences-inc-6770951)
- 2026-11-03 21:15 UTC [SEC Form 4] [Large owner Qiming Corporate Gp Vi, Ltd. sold $5,676,413 worth of shares (187,636 units at $30.25) (SEC Form 4)](https://www.quantisnow.com/insight/large-owner-qiming-corporate-gp-vi-ltd-sold-5676413-worth-6769861)
- 2026-11-03 21:10 UTC [SEC Form 8-K] [Alamar Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Financial Statements and Exhibits](https://www.quantisnow.com/insight/alamar-biosciences-inc-filed-sec-form-8-k-results-of-operations-6769679)
- 2026-11-03 21:05 UTC [Earnings] [Alamar Biosciences Reports Third Quarter 2026 Financial Results and Raises 2026 Revenue Guidance](https://www.quantisnow.com/insight/alamar-biosciences-reports-third-quarter-2026-financial-results-and-raises-6769467)
- 2026-11-03 21:03 UTC [Alamar Biosciences Partners with GSK on Large-Scale Proteomic Study to Advance Precision Medicine](https://www.quantisnow.com/insight/alamar-biosciences-partners-with-gsk-on-large-scale-proteomic-study-to-6769389)
- 2026-11-03 00:05 UTC [UPDATE -- Alamar Biosciences and Nightingale Health to Lead UK Biobank 80,000-Sample Neurodegenerative Disease Study](https://www.quantisnow.com/insight/update----alamar-biosciences-and-nightingale-health-to-lead-uk-6768027)
- 2026-11-02 13:00 UTC [Alamar Biosciences and Nightingale Health to Lead UK Biobank 80,000-Sample Neurodegenerative Disease Study](https://www.quantisnow.com/insight/alamar-biosciences-and-nightingale-health-to-lead-uk-biobank-80000-sample-6766178)
- 2026-10-29 20:09 UTC [SEC Form 4] [Large owner Qiming Corporate Gp Vi, Ltd. sold $5,968,888 worth of shares (185,731 units at $32.14) (SEC Form 4)](https://www.quantisnow.com/insight/large-owner-qiming-corporate-gp-vi-ltd-sold-5968888-worth-6763573)
- 2026-10-28 20:05 UTC [Emory Researchers Identify Blood Protein Signature That Detects ALS With 98% Accuracy Using Alamar Technology](https://www.quantisnow.com/insight/emory-researchers-identify-blood-protein-signature-that-detects-als-with-6761165)
- 2026-10-27 20:10 UTC [SEC Form 4] [Large owner Qiming Corporate Gp Vi, Ltd. sold $8,569,760 worth of shares (280,458 units at $30.56) (SEC Form 4)](https://www.quantisnow.com/insight/large-owner-qiming-corporate-gp-vi-ltd-sold-8569760-worth-6759292)
- 2026-10-23 23:35 UTC [SEC Form 4] [Large owner Qiming Corporate Gp Vi, Ltd. sold $10,253,095 worth of shares (342,626 units at $29.93) (SEC Form 4)](https://www.quantisnow.com/insight/large-owner-qiming-corporate-gp-vi-ltd-sold-10253095-worth-6756690)
- 2026-10-21 23:15 UTC [SEC Form 4] [Large owner Qiming Corporate Gp Vi, Ltd. sold $5,949,983 worth of shares (217,512 units at $27.35) (SEC Form 4)](https://www.quantisnow.com/insight/large-owner-qiming-corporate-gp-vi-ltd-sold-5949983-worth-6753986)
- 2026-10-19 20:30 UTC [SEC Form 4] [Large owner Qiming Corporate Gp Vi, Ltd. sold $4,816,121 worth of shares (173,673 units at $27.73) (SEC Form 4)](https://www.quantisnow.com/insight/large-owner-qiming-corporate-gp-vi-ltd-sold-4816121-worth-6750789)
- 2026-10-15 00:33 UTC [SEC Form 144] [SEC Form 144 filed by Alamar Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-144-filed-by-alamar-biosciences-inc-6747032)
- 2026-10-15 00:23 UTC [SEC Form 144] [SEC Form 144 filed by Alamar Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-144-filed-by-alamar-biosciences-inc-6747028)
- 2026-10-15 00:20 UTC [SEC Form 144] [SEC Form 144 filed by Alamar Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-144-filed-by-alamar-biosciences-inc-6747026)
- 2026-10-15 00:15 UTC [SEC Form 144] [SEC Form 144 filed by Alamar Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-144-filed-by-alamar-biosciences-inc-6747024)
- 2026-10-08 20:05 UTC [Earnings Date] [Alamar Biosciences to Report Third Quarter 2026 Financial Results on November 3, 2026](https://www.quantisnow.com/insight/alamar-biosciences-to-report-third-quarter-2026-financial-results-on-6741727)
- 2026-10-05 20:05 UTC [Leadership Update] [Alamar Biosciences Names Former Grail CEO Bob Ragusa to Board of Directors and Expands Leadership Team](https://www.quantisnow.com/insight/alamar-biosciences-names-former-grail-ceo-bob-ragusa-to-board-6736669)
- 2026-09-24 22:51 UTC [Lancet Neurology Study Using Alamar Biosciences’ Technology Reveals Divergent Biological Responses to Alzheimer’s Treatment](https://www.quantisnow.com/insight/lancet-neurology-study-using-alamar-biosciences-technology-reveals-divergent-biological-6725825)
- 2026-09-16 20:20 UTC [SEC Form 4] [General Counsel Brottem John L. was granted 29,000 shares (SEC Form 4)](https://www.quantisnow.com/insight/general-counsel-brottem-john-l-was-granted-29000-shares-sec-6717623)
- 2026-09-16 20:19 UTC [SEC Form 3] [SEC Form 3 filed by new insider Brottem John L.](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-brottem-john-l-6717614)
- 2026-09-03 20:27 UTC [SEC Form 4] [Director Ragusa Robert P was granted 5,686 shares (SEC Form 4)](https://www.quantisnow.com/insight/director-ragusa-robert-p-was-granted-5686-shares-sec-form-6705334)
- 2026-09-03 20:26 UTC [SEC Form 3] [SEC Form 3 filed by new insider Ragusa Robert P](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-ragusa-robert-p-6705307)
- 2026-09-01 20:05 UTC [Conference Announcement] [Alamar Biosciences to Participate in Morgan Stanley 24th Annual Global Healthcare Conference](https://www.quantisnow.com/insight/alamar-biosciences-to-participate-in-morgan-stanley-24th-annual-global-6701308)
- 2026-09-01 20:01 UTC [SEC Form 8-K] [SEC Form 8-K filed by Alamar Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-alamar-biosciences-inc-6701274)
- 2026-08-11 20:39 UTC [SEC Form SCHEDULE 13G filed by Alamar Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-schedule-13g-filed-by-alamar-biosciences-inc-6676237)
- 2026-08-11 00:30 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Alamar Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-alamar-biosciences-inc-6674705)
- 2026-08-10 20:10 UTC [SEC Form 8-K] [Alamar Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/alamar-biosciences-inc-filed-sec-form-8-k-results-of-operations-6673715)
- 2026-08-10 20:05 UTC [Earnings Date] [Alamar Biosciences Reports Second Quarter 2026 Financial Results and Provides 2026 Revenue Guidance](https://www.quantisnow.com/insight/alamar-biosciences-reports-second-quarter-2026-financial-results-and-provides-6673536)
- 2026-08-10 20:03 UTC [Alamar Biosciences Expands Global Partnership with Alzheimer’s Disease Data Initiative and Gates Ventures](https://www.quantisnow.com/insight/alamar-biosciences-expands-global-partnership-with-alzheimers-disease-data-initiative-6673470)
- 2026-07-28 20:12 UTC [Alamar Biosciences Launches NULISAseq™ Immune 340 Panel for Comprehensive Profiling of the Immune Proteome](https://www.quantisnow.com/insight/alamar-biosciences-launches-nulisaseq-immune-340-panel-for-comprehensive-profiling-6651516)
- 2026-07-15 20:04 UTC [SEC Form 8-K] [SEC Form 8-K filed by Alamar Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-alamar-biosciences-inc-6638199)
- 2026-07-14 20:05 UTC [Earnings Date] [Alamar Biosciences to Report Second Quarter 2026 Financial Results on August 10, 2026](https://www.quantisnow.com/insight/alamar-biosciences-to-report-second-quarter-2026-financial-results-on-6636697)
- 2026-07-13 06:30 UTC [Alamar Biosciences Partners with Leading Research Universities to Launch National Initiative Advancing Blood-Based Biomarkers for Neurodegenerative Diseases](https://www.quantisnow.com/insight/alamar-biosciences-partners-with-leading-research-universities-to-launch-national-6634600)
- 2026-07-07 20:55 UTC [Amendment: SEC Form SCHEDULE 13D/A filed by Alamar Biosciences Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13da-filed-by-alamar-biosciences-inc-6630336)
- 2026-07-07 13:12 UTC [Alamar Biosciences Launches the First Multiplexed Blood-based Immunoassay for eMTBR-Tau, One of the Most Important Biomarkers in Alzheimer’s Disease Research](https://www.quantisnow.com/insight/alamar-biosciences-launches-the-first-multiplexed-blood-based-immunoassay-for-emtbr-tau-6629752)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/ALMR
- Earnings history: https://www.quantisnow.com/earnings/ALMR
- Dividend history: https://www.quantisnow.com/dividends/ALMR
- Insider transactions: https://www.quantisnow.com/insiders/ALMR
- Options chain: https://www.quantisnow.com/options/ALMR
- SEC 8-K filings only: https://www.quantisnow.com/company/ALMR/8-k
- RSS and alerts for ALMR: https://www.quantisnow.com/docs/rss-feeds.md